Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C
Open accessThe DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
NAFLD (non-alcoholic fatty liver disease) is one of the most frequent chronic liver diseases worldwide. The metabolic factors associated with NAFLD are also determinants of liver disease progression in chronic HCV (hepatitis C virus) infection. It has been reported that, besides inducing hepatic fatty acid biosynthesis, LXR (liver X receptor) regulates a set of inflammatory genes. We aimed to evaluate the hepatic expression of LXRα and its lipogenic and inflammatory targets in 43 patients with NAFLD, 44 with chronic HCV infection and in 22 with histologically normal liver. Real-time PCR and Western blot analysis were used to determine hepatic expression levels of LXRα and related lipogenic and inflammatory mediators in the study population. We found that the LXRα gene and its lipogenic targets PPAR-γ (peroxisome-proliferator-activated receptor-γ), SREBP (sterol-regulatory-element-binding protein)-1c, SREBP-2 and FAS (fatty acid synthase) were overexpressed in the liver of NAFLD and HCV patients who had steatosis. Moreover, up-regulation of inflammatory genes, such as TNF (tumour necrosis factor)-α, IL (interleukin)-6, OPN (osteopontin), iNOS (inducible NO synthase), COX (cyclo-oxygenase)-2 and SOCS (suppressors of cytokine signalling)-3, was observed in NAFLD and HCV patients. Interestingly, TNF-α, IL-6 and osteopontin gene expression was lower in patients with steatohepatitis than in those with steatosis. In conclusion, hepatic expression of LXRα and its related lipogenic and inflammatory genes is abnormally increased in NAFLD and HCV patients with steatosis, suggesting a potential role of LXRα in the pathogenesis of hepatic steatosis in these chronic liver diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The increase in DNL, often observed in metabolic diseases, is also due to the overactivation of the transcription factors that stimulate DNL, e.g. sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate-responsive-element-binding-protein (ChREBP), which can promote the development of MASLD.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [28]
In the citing paper
“In fact, LXR is a cholesterol sensor, with a central role in the inflammatory control and in the regulation of lipid and glucose metabolism, overexpressed in case of hepatic steatosis [125].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [125]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Classification of chronic viral hepatitis: a need for reassessment
Scheuer, P. J. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90084-o · Cited by 1,576
Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Nature Medicine · doi:10.1038/nm820 · Cited by 1,158
LXR, a nuclear receptor that defines a distinct retinoid response pathway.
Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., & Mangelsdorf, D. J. (1995) · Genes & Development · doi:10.1101/gad.9.9.1033 · Cited by 1,123
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Cited by
Items 101–142 of 142
Perturbations of Lipid Metabolism Indexed by Lipidomic Biomarkers
Lamazière, A., Wolf, C., & Quinn, P. J. (2012) · Metabolites · doi:10.3390/metabo2010001 · Cited by 13
Wang, G., Chen, S., Zhao, C., Li, X., Zhao, W., Yang, J., Chang, C., & Xu, C. (2016) · Journal of Genetics · doi:10.1007/s12041-016-0673-7 · Cited by 12
“Compared with the normal group, the mRNA level of OPN was significantly increased in NAFLD patients (Lima-Cabello et al. 2011).”
BackgroundCai, C., Luo, H., Jin, P., Zhen, X., Shen, X., Xi, X., Zhu, J., Fang, Y., Chen, X., Wang, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.046 · Cited by 11
Wang, J., Dong, L., Hu, J., Wang, Y.-Y.-F., Li, A., Peng, B., Zhang, B., Liu, J., & Wang, S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.992815 · Cited by 12
“LXR is a nuclear receptor that plays a vital role in the lipid synthesis of the liver (20).”
BackgroundPogribny, I. P., & Beland, F. A. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.783817 · Cited by 12
Wang, Y., Liu, Z., Zou, W., Hong, H., Fang, H., & Tong, W. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.70 · Cited by 12
Mahajan, S., Saini, A., Kalra, R., & Gupta, P. K. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2014.970122 · Cited by 11
“Both Hepatitis B virus (HBV) and Hepatitis C virus (HCV) also influence PPARg signaling as the liver of individuals infected with either HBV or HCV have elevated levels of PPARg expression (Lima-Cabello et al., 2011; Niu et al., 2011).”
BackgroundXie, X., GUO, A., Wu, T., Hu, Q., Huang, L., YAO, C., ZHAO, B., ZHANG, W., Chi, B., Lü, P., et al. (2017) · Physiological Research · doi:10.33549/physiolres.933543 · Cited by 10
“Such increased expression could be suppressed by L-Carnitine administration, suggesting L-Carnitine might be beneficial for hepatic steatosis, hyperlipidemia, and atherosclerosis (Li et al. 2011, Lima-Cabello et al. 2011).”
BackgroundMai, C.-T., Zheng, D.-C., Li, X., Zhou, H., & Xie, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105747 · Cited by 10
PPARs and HCV-Related Hepatocarcinoma: A Mitochondrial Point of View
Agriesti, F., Tataranni, T., Ruggieri, V., Capitanio, N., & Piccoli, C. (2012) · PPAR Research · doi:10.1155/2012/605302 · Cited by 9
“infected with HCV, with the highest levels in patients with HCV-associated steatosis [92].”
BackgroundThe interaction between HCV and nuclear receptor-mediated pathways
Raglow, Z., Thoma-Perry, C., Gilroy, R. K., & Wan, Y. Y. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.05.005 · Cited by 9
The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease
Francque, S. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.1.10 · Cited by 9
Santinha, D. R., Kłopot, A., Marques, I., Ellis, E. C. S., Jorns, C., Johansson, H., Melo, T., Antonson, P., Jakobsson, T., Félix, V., et al. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105558 · Cited by 9
Endocytosis of LXRs: Signaling in liver and disease
Brahma, M., Ghosal, S., Maruthi, M., & Kalangi, S. K. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.07.008 · Cited by 9
NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease
Sanal, M. G., Gish, R. G., Méndez‐Sánchez, N., Yu, M., Chan, W., Wei, L., Grønbæk, H., Zheng, M., & George, J. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.54 · Cited by 6
The potential of signal peptide peptidase as a therapeutic target for hepatitis C
Moriishi, K. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1369959 · Cited by 7
Guo, C., Qiao, J., Zhang, S., Li, M., Li, J., & Hatab, S. R. (2019) · Journal of Oleo Science · doi:10.5650/jos.ess19078 · Cited by 5
Structural Proteins of HCV and Biological Functions
Moriishi, K., & Matsuura, Y. (2016) · Springer eBooks · doi:10.1007/978-4-431-56098-2_6 · Cited by 3
Role of Nutrient and Energy Sensors in the Development of Type 2 Diabetes
Hurtado-Carneiro, V., Pérez-García, A., Álvarez, E., & Sanz, C. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95454 · Cited by 4
Albhaisi, S. A. M., & Sanyal, A. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00121-3 · Cited by 2
Hypertriglyceridemia and Non-Alcoholic Fatty Liver Disease in Metabolic Syndrome and Type 2 Diabetes
Tangvarasittichai, S. (2018) · Diabetes & Obesity International Journal · doi:10.23880/doij-16000188 · Cited by 2
“Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, et al. (2008) Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.”
BackgroundLiu, Y.-Y., Qin, H. X., Wu, H., Ru-Ting, W. A. N. G., Yang, Q.-Y., Jiang, F., Liu, X.-D., Wu, D.-K., & Tang, Y.-M. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i2.115763 · Cited by 1
Singh, M., Steinke, I., Crall, N., Tamhankar, S. P., Wibowo, F. S., Xavier, J., Yue, Z., Pondugula, S. R., Huang, C. J., Griffett, K., et al. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00240 · Cited by 2
Berlanga, A., Guiu‐Jurado, E., Porras, J. A., Aragonès, G., & Auguet, T. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.03.003 · Cited by 4
(2011) · Gastroenterología y Hepatología Continuada · doi:10.1016/s1578-1550(11)70046-8 · Cited by 1
“Más concretamente, los autores encontraron unas concentraciones anormalmente elevadas lFC en el hígado de ratones con EHNA demostraron que este metaobolito inducía apoptosis hepatocitaria tanto in vitro como in”
Hepatitis C: Viral Features and Clinical Aspects
da Silva, N. M. O., & Zanella, R. D. C. (2016) · Journal of Prevention and Infection Control · doi:10.21767/2471-9668.100025 · Cited by 1
Pisonero‐Vaquero, S. (2014) · Dialnet (Universidad de la Rioja)
Wahlang, B. (2014) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/1733
“49 Aroclor 1260 exposure modulated hepatic fat metabolism Liver-X-receptor (LXR) is the key transcription factor that drives lipid synthesis and cholesterol metabolism and its over-activation can promote or worsen steatosis (93).”
BackgroundTiburcio, T. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.10.2016.tde-11052016-141902
Berlanga, A. (2015) · TDX (Tesis Doctorals en Xarxa)
Quantifying the effects of high fructose feeding on the intestinal permeability of endotoxins
dos Santos, C. D. A. F. C. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Bécares, N., Gage, M., Martin‐Gutierrez, L., Shrestha, E., Louie, R., Pourcet, B., Pello, Ó. M., Luong, T. V., Goñi, S., Liang, N., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/127779
“Previous studies focused their efforts at establishing changes in LXRα expression and reported induced levels of LXRα present in steatotic, inflammatory and fibrotic livers (37,38).”
BackgroundEffects of LXRα phosphorylation on the regulation of lipid metabolism and hepatic fibrosis
Bécares, N. (2017) · UCL Discovery (University College London)
Pisonero‐Vaquero, S. (2014) · Buleria (Universidad de León) · doi:10.18002/10612/4183
The role relationship played by immune cells and circulating inflammatory proteins in NAFLDPreprint
Chi, Z., Zhang, Y., Bai, X., Zhao, B., & Zhang, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-4427607/v1
Güneş, A., Jeromson, S., Schmitt, C., Schoumacher, M., Eng, J., Besse‐Patin, A., Léveillé, M., Monteillet, L., Jouvet, N., Baldwin, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.09.674670
Integrated bioinformatics decoding of the MASLD ceRNA network reveals novel therapeutic targets
Yu, S., Jiang, X., Peng, L., Zeng, X., Wen, S., Xiong, H., Guo, S., Huang, F., Liu, H., & Luo, Q. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01890-x · Cited by 1
“…pro-inflammatory effect of IL-6 may be mediated by the inhibition of the cytokine signaling-3 (SOCS-3)-sterol regulatory element binding protein-1c (SREBP −1c)-lipoyl coenzyme A (FA-CoA) pathway, which inhibits insulin signaling and regulates acute phase response and chronic inflammation [30–32].”
Rôle de LECT2 dans les maladies stéatosiques non alcooliques du foie
Pham, S. (2020) · theses.fr (ABES) · doi:10.70675/3693bfe6z9d91z4045za9a9zc37497dc9c1b
Patodia, A., Karthik, H., Basu, S., Venkatesan, V., Pandey, R., & Balachander, G. M. (2026) · Natural Sciences · doi:10.1002/ntls.70069
“Transcriptional repressors of lipogenesis under pro-inflammatory conditions have been previously reported, where inflammatory cytokines like TNF-α and IL-6 inhibit SREBP-mediated fatty acid synthesis [ 59 ].”
Hayes, C. M., Cross, D. R., Achour, B., & Ghonem, N. S. (2026) · Cells · doi:10.3390/cells15161442
“In patients with MASH, the expression of miR-130a-3p, the 3 ′ arm of miR-130a [74], is substantially reduced [75], and the expression of hepatic PPAR γ mRNA (>2-fold) and protein (>1.5-fold) is significantly increased [76] relative to healthy livers.”
Influential
Metadata
- Authors
- Lima-Cabello, E., García-Mediavilla, M. V., Miquilena-Colina, M. E., Vargas-Castrillón, J., Lozano-Rodríguez, T., Fernández-Bermejo, M., Olcoz, J. L., González-Gallego, J., García-Monzón, C., & Sánchez-Campos, S.
- Affiliations
- Institute of Biomedicine (IBIOMED), University of León, León, Spain
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
- Gastroenterology Service, San Pedro de Alcántara Hospital, Cáceres, Spain
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2010-12-03
- Volume
- 120
- Issue
- 6
- Pages
- 239-250
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2005558543
- Cited by
- 144
- References
- 45
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 8 · 2018: 5 · 2017: 11 · 2016: 11 · 2015: 17 · 2014: 17 · 2013: 11 · 2012: 12
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-06-19)
- Open access
- bronze
- doi.org
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Funders
- Fundación Eugenio Rodríguez Pascual
- Junta de Castilla y León
- Instituto de Salud Carlos III
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- non-alcoholic fatty liver disease, hepatitis C, liver X receptor alpha, hepatic steatosis, steatohepatitis, pro-inflammatory gene expression, lipogenic genes, PPARγ, SREBP-1c, SREBP2, fatty acid synthase, TNF-α, interleukin-6, osteopontin, inducible nitric oxide synthase, cyclooxygenase-2, liver inflammation
- MeSH terms
- Liver X Receptors, Adult, Fatty Liver, Female, Gene Expression Regulation, Humans, Liver, Male, Middle Aged, Up-Regulation, Oxidative Stress, Inflammation Mediators, Hepatitis C, Chronic, Lipogenesis, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.